Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Longeveron Inc (LGVN)

Longeveron Inc (LGVN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 4,399
  • Shares Outstanding, K 2,513
  • Annual Sales, $ 710 K
  • Annual Income, $ -21,410 K
  • 60-Month Beta 0.51
  • Price/Sales 6.42
  • Price/Cash Flow N/A
  • Price/Book 0.65
Trade LGVN with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/24
See More
  • Average Estimate -2.01
  • Number of Estimates 2
  • High Estimate -1.31
  • Low Estimate -2.70
  • Prior Year -2.20
  • Growth Rate Est. (year over year) +8.64%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.6000 +9.37%
on 04/29/24
5.4700 -68.01%
on 04/08/24
-0.7500 (-30.00%)
since 04/03/24
3-Month
1.6000 +9.37%
on 04/29/24
5.8580 -70.13%
on 02/27/24
-3.8300 (-68.64%)
since 02/02/24
52-Week
1.6000 +9.37%
on 04/29/24
44.0000 -96.02%
on 05/09/23
-28.3500 (-94.19%)
since 05/03/23

Most Recent Stories

More News
Longeveron (NASDAQ: LGVN) Schedules Release of Q1 2024 Financial Results, Earnings Conference Call

Longeveron (NASDAQ: LGVN), a clinical-stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions such as hypoplastic left heart syndrome (“HLHS”),...

LGVN : 1.7500 (-3.31%)
Longeveron (NASDAQ: LGVN) to Participate in Upcoming Planet MicroCap Showcase

Longeveron (NASDAQ: LGVN), a clinical-stage, biotechnology company developing regenerative medicines, will be presenting at next month’s Planet MicroCap Showcase. The conference is slated for May 1–2,...

LGVN : 1.7500 (-3.31%)
Longeveron (NASDAQ: LGVN) Closes on Warrant Exercise Offering, Public Offering

Longeveron (NASDAQ: LGVN), a clinical-stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions such as hypoplastic left heart syndrome (“HLHS”),...

LGVN : 1.7500 (-3.31%)
Longeveron (NASDAQ: LGVN) to Exercise Warrants for ~$6.2M

Longeveron (NASDAQ: LGVN) is a clinical stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions such as hypoplastic left heart syndrome (“HLHS”),...

LGVN : 1.7500 (-3.31%)
Longeveron (NASDAQ: LGVN) Closes on Public Offering Valued at Estimated $5.2M

Longeveron (NASDAQ: LGVN), a clinical-stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions such as hypoplastic left heart syndrome (“HLHS”),...

LGVN : 1.7500 (-3.31%)
Longeveron (NASDAQ: LGVN) Releases Pricing for Mulitmillion-Dollar Public Offering

Longeveron (NASDAQ: LGVN), a clinical-stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions such as hypoplastic left heart syndrome (“HLHS”),...

LGVN : 1.7500 (-3.31%)
Longeveron (NASDAQ: LGVN) Discusses 2023 Progress, 2024 Plans in Corporate Update

Longeveron (NASDAQ: LGVN), a clinical-stage biotechnology company developing regenerative medicine for life-threatening conditions with unmet medical needs, recently released its full-year results for...

LGVN : 1.7500 (-3.31%)
Longeveron (NASDAQ: LGVN) Board Approves 1-for-10 Reverse Stock Split

Longeveron (NASDAQ: LGVN), a clinical-stage biotechnology company developing regenerative medicines for unmet medical needs, has announced a 1-for-10 reverse split of the company’s Class A common stock....

LGVN : 1.7500 (-3.31%)
Longeveron (NASDAQ: LGVN) Reports on Year-End 2023 Financial Results

Longeveron (NASDAQ: LGVN), a clinical-stage biotechnology company developing regenerative medicines for unmet medical needs, has released a financial report for the year ended Dec. 31, 2023; the report...

LGVN : 1.7500 (-3.31%)
Longeveron (NASDAQ: LGVN) Announces Plans to Release Year-End 2023 Financial Results

Longeveron (NASDAQ: LGVN), a clinical-stage biotechnology company developing regenerative medicines for unmet medical needs, has scheduled a conference call to discuss its financial results for 2023. The...

LGVN : 1.7500 (-3.31%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Business Summary

Longeveron Inc. is a clinical stage biotechnology company. It engages in developing cellular therapies for chronic aging-related and life-threatening conditions. The company's investigational product includes LOMECEL-B(TM). Longeveron Inc. is based in MIAMI.

See More

Key Turning Points

3rd Resistance Point 1.9933
2nd Resistance Point 1.9367
1st Resistance Point 1.8433
Last Price 1.7500
1st Support Level 1.6933
2nd Support Level 1.6367
3rd Support Level 1.5433

See More

52-Week High 44.0000
Fibonacci 61.8% 27.8032
Fibonacci 50% 22.8000
Fibonacci 38.2% 17.7968
Last Price 1.7500
52-Week Low 1.6000

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar